Biosimilar in Lung Cancer

In recent years, the development and clinical integration of biosimilar therapies have garnered significant attention in the field of oncology. An updated summary of function of biosimilar in treatment of lung cancer (LC) is given in this thorough review. The availability, cost of efficient therapy alternatives are crucial because LC is primary reason for cancer-related deaths globally. Biosimilar has become a promising means of increasing patient access to life-saving therapies because they provide efficacy and safety profiles that are comparable to those of reference biologics. This study explores the current state of biosimilar in the treatment of LC, taking into account legislative frameworks, clinical studies, and empirical data. It also discusses important issues related to extrapolation, interchangeability, and pharmacovigilance. In particular, the financial effects and cost-effectiveness of biosimilar in the treatment of LC are explored, giving light on their potential to reduce financial burdens on healthcare systems and individuals alike. The review also emphasizes certain biosimilar drugs and their therapeutic applications in LC, with a focus on important trials and results. The effect of biosimilar on patient outcomes, quality of life, and the use of medical resources is given particular consideration. Finally, the study provides information on current research projects and potential developments in the field of LC biosimilar medicines. Exciting prospects to transform therapy paradigms, improve patient access, and optimize healthcare budget allocation are presented by the emerging biosimilar landscape in oncology.